Aging and renal clearance of procainamide and acetylprocainamide

Clinical Pharmacology and Therapeutics
M M ReidenbergD E Drayer

Abstract

Thirty-two patients had blood and urine collected simultaneously for measurement of procainamide, acetylprocainamide, and creatinine. The ratios of drug clearance to creatinine clearance were calculated for each. The procainamide:creatinine clearance ratio averaged 2.9 +/- 1.6 (SD) and fell as age of the patients rose (r = 0.5, p < 0.01). The acetylprocainamide:creatinine clearance ratio averaged 1.7 +/- 0.8 and also fell with age. The combination of decline in overall renal function with age with this decrease in the rate of renal tubular secretion of these drugs led to a progressive age-related rise in the steady-state serum level of procainamide (r = 0.56, p < 0.01) and acetylprocainamide (r = 0.36, p < 0.1) achieved by any dose of procainamide. Thus, the dosage of procainamide must be individualized for both overall renal function (GFR) and the age-related variations in renal tubular secretion that are of most note in children and the elderly.

Citations

Feb 1, 1992·Journal of Clinical Pharmacology·M Piquette-MillerF Jamali
Jan 1, 1990·British Journal of Clinical Pharmacology·A SomogyiF Bochner
Nov 1, 1985·British Journal of Clinical Pharmacology·J BondeJ P Kampmann
Oct 1, 1984·Journal of the American Geriatrics Society·D R Abernethy, L Kerzner
Nov 1, 1983·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·J P VilleneuveD Arsène
Oct 1, 1994·The Annals of Pharmacotherapy·E M LandrumM S Currie
Apr 1, 1990·Journal of the American Geriatrics Society·L A BauerA Gensler
Mar 1, 1985·British Journal of Clinical Pharmacology·D J ChapronP A Kramer
Jan 1, 1984·Annals of the New York Academy of Sciences·P A Routledge
Aug 1, 1997·Clinical Pharmacology and Therapeutics·M R UjhelyiM L Markel
Apr 1, 1991·Journal of Pharmacokinetics and Biopharmaceutics·A Maiza, P T Daley-Yates
Jan 1, 1988·European Journal of Clinical Pharmacology·J H LinG A Hessey
Aug 3, 1989·The New England Journal of Medicine·S C MontamatR E Vestal
Jan 1, 1984·Annals of the New York Academy of Sciences·R E Kates
Oct 21, 1982·The New England Journal of Medicine·A Somogyi, B Heinzow
May 6, 1982·The New England Journal of Medicine·D J GreenblattR I Shader
Sep 19, 2008·Expert Opinion on Drug Metabolism & Toxicology·Sarah N Hilmer
Jul 27, 2002·Pharmacogenetics·Maya K LeabmanUNKNOWN Pharmacogenetics of Membrane Transporters Investigators
Apr 1, 1984·Australian and New Zealand Journal of Medicine·P C Ho, E J Triggs
May 21, 2013·Pharmacological Reviews·Jörg KönigMartin F Fromm
Jan 1, 1987·European Journal of Clinical Pharmacology·E Lunell, O Borgå
Jun 1, 2001·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Y L HeR Hori
Apr 23, 2005·Toxicology and Applied Pharmacology·Stephen H Wright
May 21, 2005·The American Journal of Geriatric Pharmacotherapy·Barry J Cusack
Dec 21, 2005·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Christopher J EndresJashvant D Unadkat

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of the American Geriatrics Society
L A BauerA Gensler
Clinical Pharmacokinetics
S J Connolly, R E Kates
Clinical Pharmacology and Therapeutics
M M ReidenbergH Warner
International Journal of Clinical Pharmacology, Therapy, and Toxicology
P Ylitalo, H Hinkka
© 2021 Meta ULC. All rights reserved